Why the study?
Does TS-951 affect action potential parameters in isolated rabbit myocardium compared to cisapride?
Does TS-951 affect action potential parameters in isolated rabbit myocardium compared to cisapride?
TS-951, unlike cisapride, does not prolong action potential duration in ventricular myocardium, suggesting a lower risk of QT prolongation and torsades de pointes.
Answers are grounded in this paper and cite their sources.
May indicate lower proarrhythmic potential for TS-951 than cisapride; hypothesis-generating for clinical use and should not yet change practice.
The effects of TS-951, a novel gastrointestinal prokinetic agent with 5-HT(4) receptor agonistic action, on the action potential parameters of isolated rabbit Purkinje fiber, ventricular muscle and sinoatrial node, and on the spontaneously beating rates of isolated rabbit right atria were compared with those of cisapride. TS-951 had no effect on the action potential parameters in both rabbit Purkinje fiber and ventricular muscle preparations. However, cisapride significantly prolonged action potential duration (APD) in both preparations. Both TS-951 and cisapride produced a negative chronotropic effect in rabbit right atria; TS-951 and cisapride at 3 x 10(-5) mol/l reduced the beating rate by about 20 and 40%, respectively. In the sinoatrial node preparations, TS-951 (3 x 10(-5) mol/l) as well as cisapride (10(-6) mol/l) prolonged cycle length and APD and reduced the diastolic depolarization rate. These results indicate that TS-951 does not appear to possess electrophysiological features leading to cardiotoxicity such as QT prolongation and, thus, torsades de pointes in common with cisapride.
No takes yet. Share an insight, caveat, or question.
Noguchi et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: